Bronchiolitis (RSV)
Patient < 2 y/o with h/o eczema and no h/o intubation presents in January with increased respiratory effort. Parents report 3 days of increasing cough and decreased oral intake. Sick contacts include siblings and other children at daycare. Initial SPO2 94%. Low grade fever, tachycardia, rhinorrhea, nasal flaring, dry mucous membranes, grunting, mild retractions, and wheezing/crackles on exam.
Obtain daily weights to assess hydration status
Do not obtain virus panel
CXR shows non-specific peribronchiolar cuffing, hyperinflation, and atelectasis
Treatment
Start supplemental (blow-by) oxygen to maintain SPO2 > 90%
Nasal suction bulb PRN; avoid over-suctioning and/or deep suction
Respiratory rate > 60 breath/min or unable to maintain sufficient PO intake: Administer fluids via IV and/or nasogastric tube
Weight > 2.7 kg (6 lbs): Acetaminophen q6h PRN fever
Age > 6 months, weight > 5.4 kg (12 lbs): Ibuprofen q6h PRN fever
Counseling
Parents counseled that symptoms typically peak at 2-3 days and last 7-10 days
Parents reassured that it is unlikely a child will be hospitalized during the full illness course
Parents educated about the importance of hand washing and avoidance of second hand smoke to reduce risk for future respiratory infection
Notes
Lower respiratory tract infection most commonly caused by respiratory syncytial virus (RSV)
Peak season: December through March
Prophylaxis
Palivizumab: RSV monoclonal antibody administered monthly during peak RSV season (maximum 5 doses)
Administer to infants
Born before 29 WGA
Born before 32 WGA with chronic lung disease of prematurity
With hemodynamically significant heart disease
Diagnosis and treatment
Respiratory virus panels (PCR) cost between $1,000 and $3,500 and do not change management
Routine CXR is not recommended
Continuous pulse oximetry is not required
Treatment such as albuterol, epinephrine, corticosteroids, and/or antibiotics are ineffective and should be avoided
Infants with respiratory rates > 60 breaths/min may demonstrate poor feeding and benefit from NG tube or IV hydration
Predictors of severity
Safe discharge predicted by age > 2 months, no h/o intubation, h/o eczema, initial SPO2 of 94%, and adequate oral intake
More concerning s/sx include tachycardia, evidence of dehydration (decreased weight, dry mucous membranes), and increased respiratory effort